Refine
Year of publication
Document Type
- Preprint (688)
- Article (508)
- Conference Proceeding (3)
- Working Paper (1)
Has Fulltext
- yes (1200)
Is part of the Bibliography
- no (1200)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- HIV (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- breast cancer (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- coronavirus (3)
- pp collisions (3)
- Beauty production (2)
- Breast cancer (2)
- COVID-19 (2)
- CRM (2)
- Charm physics (2)
- Diagnostik (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Heavy Quark Production (2)
- Hepatitis C virus (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Single electrons (2)
- biomarker (2)
- brain metastases (2)
- cirrhosis (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- guidelines (2)
- reference values (2)
- screening (2)
- stroke (2)
- 900 GeV (1)
- AA-amylodosis (1)
- ABC transporters (1)
- ACLF (1)
- ADHD (1)
- ALICE detector (1)
- APRI (1)
- ASAP (1)
- ATAD2 (1)
- ATPases (1)
- Abrasion (1)
- Adverse events (1)
- Alien (1)
- Alternating Phase Focusing (1)
- Anti-nuclei (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Artesunate (1)
- Atmospheric science (1)
- B cell subpopulations (1)
- BRCA1 (1)
- BRCA2 (1)
- BRD2 (1)
- BRD4 (1)
- BROMO-10 (1)
- Baryonic resonances (1)
- Beam dynamics simulation (1)
- Big Five (1)
- Biodiversity (1)
- Biogeographical representativeness (1)
- Boosted Jets (1)
- CD16 (1)
- CD56 (1)
- CDH13 (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Central nervous system metastases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Chemoradiotherapy (1)
- Chemorefractory advanced gastric cancer (1)
- Child (1)
- Child abuse (1)
- Children (1)
- Chronic kidney disease (1)
- Cirrhosis (1)
- Claims on land (1)
- Climate change (1)
- Clinical genetics (1)
- Clinical study (1)
- Clinical variation (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Consensus (1)
- Continuous wave (1)
- Cytoskeleton (1)
- Data management (1)
- Decision trees (1)
- Decontamination (1)
- Dental air (1)
- Dental implants (1)
- Depression (1)
- Dermatomyositis (1)
- Devic disease (1)
- Devic syndrome (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Docetaxel (1)
- Drug therapy (1)
- EBV (1)
- Ecosystem integrity (1)
- Ecosystem services (1)
- Ecosystems (1)
- Elderly (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Emotions (1)
- Entomology (1)
- Environment (1)
- Ephrin-B2–EphB4 (1)
- Essential biodiversity variables (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exosomes (1)
- Experimental models of disease (1)
- FIB-4 (1)
- FOLFIRI (1)
- FXIII deficiency (1)
- Factor XIII (1)
- Falciparum (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First site of metastatic disease (1)
- First-line combination antiretroviral therapy (1)
- Forensic examination (1)
- Forschung (1)
- Frailty (1)
- Freezeout (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics research (1)
- Genomic instability (1)
- German PID-NET registry (1)
- Gleason Score (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HIV-1 (1)
- HIV-RNA (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Heavy-ion reactions (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Human behaviour (1)
- Human well-being (1)
- Hyperons (1)
- Hypertension (1)
- IHC (1)
- IVDU (1)
- IgG substitution therapy (1)
- Immunology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- LTER (1)
- Lehre (1)
- Linear accelerator (1)
- Liver diseases (1)
- Liver enzymes (1)
- Liver transplantation (1)
- Long-term ecological monitoring (1)
- Long‐term ecosystem research (1)
- MRI (1)
- MS (1)
- Malaria (1)
- Material budget (1)
- Mental health and psychiatry (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular medicine (1)
- Molecular neuroscience (1)
- Mongolian spot (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Myanmar (1)
- NK cells (1)
- NMO-IgG (1)
- NSAIDs (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neuromyelitis optica (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Noninferiority (1)
- Nonlinear beam dynamics (1)
- Nuclear modification factor (1)
- Nucleus (1)
- ORL (1)
- Observation (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- Osteoporosis (1)
- Otorhinolaryngology (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Peri-implantitis (1)
- Personalized medicine (1)
- Phylogenomics (1)
- Physiology (1)
- Plasmodium (1)
- Population genetics (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Predictive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Psychometrics (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Questionnaires (1)
- Quinine (1)
- Rapidity Range (1)
- Regression analysis (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SF-36 (1)
- Severe malaria (1)
- Single muons (1)
- Site networks (1)
- Socio-ecology (1)
- Specialist training (1)
- Stentoplasty (1)
- Storage ring (1)
- Strangeness (1)
- Sunitinib (1)
- Sustainability (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- TR (1)
- Teaching (1)
- Thrombosis (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Tyrosine kinase inhibitor (1)
- University hospitals (1)
- Universitätskliniken (1)
- VEGF (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- WHO-5 (1)
- Weiterbildung (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- acute-on-chronic liver failure (1)
- acute‐on‐chronic liver failure (1)
- advanced breast cancer (1)
- agreeableness (1)
- allogeneic transplantation (1)
- androgen receptor (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-retroviral agents (1)
- antibiotic resistance (1)
- antibiotics (1)
- antihormone therapy (1)
- aquaporin-4 (AQP4) antibody (1)
- asymptomatic (1)
- autoimmunity (1)
- binary nucleation (1)
- bioprinting (1)
- biosecurity (1)
- blood hiv rna (1)
- body-on-a-chip (1)
- bortezomib (1)
- bromodomain inhibitor (1)
- cART (1)
- cancer therapy (1)
- castration-resistant prostate cancer (1)
- cd4 count determination procedure (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- children (1)
- chromatin (1)
- circulation (1)
- clinical features (1)
- co-infection (1)
- complement system (1)
- concept (1)
- concordance (1)
- conservation (1)
- cryo-EM (1)
- dE/dx (1)
- detector (1)
- downgrading (1)
- e-Health (1)
- emergency care (1)
- epidemiology (1)
- everolimus (1)
- excipients (1)
- executive functions (1)
- exercise (1)
- exotic (1)
- experimental results (1)
- expertise (1)
- exponential model (1)
- fecal microbiota transfer (1)
- fibrotest (1)
- flow cytometry (1)
- fusion biopsy (1)
- graft-vs-host disease (1)
- health (1)
- heart-on-a-chip (1)
- heavy ion experiments (1)
- hemodynamic (1)
- hepatitis C (1)
- hiv (1)
- hospital admission (1)
- human allogeneic hematopoietic cell transplantation (1)
- human immunodeficiency virus (1)
- human intestinal microbiota (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- impact (1)
- induction regimen (1)
- inflammation (1)
- invasion (1)
- ion‐induced nucleation (1)
- kidney (1)
- kidney-on-a-chip (1)
- lantibiotic (1)
- lapatinib (1)
- lenalidomide (1)
- lipoprotein (1)
- liver-on-a-chip (1)
- lockdowns (1)
- longitudinally extensive transverse myelitis (1)
- lung-on-a-chip (1)
- magnetic resonance imaging (1)
- male (1)
- management (1)
- mass spectrometry (1)
- mechanical ventilation (1)
- membrane proteins (1)
- metastatic (1)
- metastatic renal cell carcinoma (1)
- micro-physiological systems (1)
- molecular machines (1)
- mortality (1)
- multiple myeloma (1)
- native (1)
- neurodevelopment (1)
- nisin binding (1)
- non-invasive fibrosis assessment (1)
- nonnative (1)
- nuclear magnetic resonance (NMR) (1)
- organs-on-a-chip (1)
- pain (1)
- pertuzumab (1)
- phase IV (1)
- phylogeny (1)
- physical activity (1)
- pleiotropy (1)
- pneumocystis carinii (1)
- pneumocystis pneumonia (1)
- pneumonia (1)
- point shear wave elastography (1)
- prevention (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- prognostic scores (1)
- prophylaxis (1)
- prostate cancer (1)
- prostate neoplasm (1)
- protein structure (1)
- psychological health (1)
- pulmonary failure (1)
- quark gluon plasma (1)
- radical prostatectomy (1)
- recurrent optic neuritis (1)
- registry for primary immunodeficiency (1)
- renal failure (1)
- respiratory failure (1)
- risk (1)
- second-line (1)
- seed and soil (1)
- sequence alignment (1)
- simulation (1)
- simulation training (1)
- skin-on-a-chip (1)
- small angle x-ray scattering (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- stakeholder (1)
- structural biology (1)
- systematic biopsy (1)
- telemedicine (1)
- thrombolysis (1)
- thrombolysis (tPA) (1)
- training (1)
- transient elastography (1)
- trastuzumab (1)
- uncertainty (1)
- upgrading (1)
- valuation (1)
- working memory (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1088)
- Frankfurt Institute for Advanced Studies (FIAS) (957)
- Informatik (920)
- Medizin (72)
- Geowissenschaften (12)
- Biochemie und Chemie (7)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- ELEMENTS (3)
- Informatik und Mathematik (3)
Objective: We aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within 1 month from first dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany. Methods: A web-based questionnaire was e-mailed to all departments of neurology. We requested a report of cases of CVT occurring within 1 month of a COVID-19 vaccination. Other cerebral events could also be reported. Incidence rates of CVT were calculated by using official statistics of 9 German states. Results: A total of 45 CVT cases were reported. In addition, 9 primary ischemic strokes, 4 primary intracerebral hemorrhages, and 4 other neurological events were recorded. Of the CVT patients, 35 (77.8%) were female, and 36 (80.0%) were younger than 60 years. Fifty-three events were observed after vaccination with ChAdOx1 (85.5%), 9 after BNT162b2 (14.5%) vaccination, and none after mRNA-1273 vaccination. After 7,126,434 first vaccine doses, the incidence rate of CVT within 1 month from first dose administration was 0.55 (95% confidence interval [CI] = 0.38–0.78) per 100,000 person-months (which corresponds to a risk of CVT within the first 31 days of 0.55 per 100,000 individuals) for all vaccines and 1.52 (95% CI = 1.00–2.21) for ChAdOx1 (after 2,320,535 ChAdOx1 first doses). The adjusted incidence rate ratio was 9.68 (95% CI = 3.46–34.98) for ChAdOx1 compared to mRNA-based vaccines and 3.14 (95% CI = 1.22–10.65) for females compared to non-females. In 26 of 45 patients with CVT (57.8%), VITT was graded highly probable. Interpretation: Given an incidence of 0.02 to 0.15 per 100,000 person-months for CVT in the general population, these findings point toward a higher risk for CVT after ChAdOx1 vaccination, especially for women.
Organ-on-a-chip technology has the potential to accelerate pharmaceutical drug development, improve the clinical translation of basic research, and provide personalized intervention strategies. In the last decade, big pharma has engaged in many academic research cooperations to develop organ-on-a-chip systems for future drug discoveries. Although most organ-on-a-chip systems present proof-of-concept studies, miniaturized organ systems still need to demonstrate translational relevance and predictive power in clinical and pharmaceutical settings. This review explores whether microfluidic technology succeeded in paving the way for developing physiologically relevant human in vitro models for pharmacology and toxicology in biomedical research within the last decade. Individual organ-on-a-chip systems are discussed, focusing on relevant applications and highlighting their ability to tackle current challenges in pharmacological research.
Abrasion-ablation models and the empirical EPAX parametrization of projectile fragmentation are described. Their cross section predictions are compared to recent data of the fragmentation of secondary beams of neutron-rich, unstable 19,20,21O isotopes at beam energies near 600 MeV/nucleon as well as data for stable 17,18O beams.
The neutron sensitivity of the C6D6 detector setup used at n_TOF facility for capture measurements has been studied by means of detailed GEANT4 simulations. A realistic software replica of the entire n_TOF experimental hall, including the neutron beam line, sample, detector supports and the walls of the experimental area has been implemented in the simulations. The simulations have been analyzed in the same manner as experimental data, in particular by applying the Pulse Height Weighting Technique. The simulations have been validated against a measurement of the neutron background performed with a natC sample, showing an excellent agreement above 1 keV. At lower energies, an additional component in the measured natC yield has been discovered, which prevents the use of natC data for neutron background estimates at neutron energies below a few hundred eV. The origin and time structure of the neutron background have been derived from the simulations. Examples of the neutron background for two different samples are demonstrating the important role of accurate simulations of the neutron background in capture cross-section measurements.
The neutron capture cross section of 58Ni was measured at the neutron time of flight facility n_TOF at CERN, from 27 meV to 400 keV neutron energy. Special care has been taken to identify all the possible sources of background, with the so-called neutron background obtained for the first time using high-precision GEANT4 simulations. The energy range up to 122 keV was treated as the resolved resonance region, where 51 resonances were identified and analyzed by a multilevel R-matrix code SAMMY. Above 122 keV the code SESH was used in analyzing the unresolved resonance region of the capture yield. Maxwellian averaged cross sections were calculated in the temperature range of kT = 5 – 100 keV, and their astrophysical implications were investigated.
Fission fragment mass distributions were measured in heavy-ion induced fissions using 238U target nucleus. The measured mass distributions changed drastically with incident energy. The results are explained by a change of the ratio between fusion and qasifission with nuclear orientation. A calculation based on a fluctuation dissipation model reproduced the mass distributions and their incident energy dependence. Fusion probability was determined in the analysis, and the values were consistent with those determined from the evaporation residue cross sections.
Competition over land is at the core of many sustainable development challenges in Myanmar: villagers, companies, governments, ethnic minority groups, civil society organisations and non-governmental organisations from local to the international level claim access to and decision-making power over the use of land. Therefore, this article investigates the actor interactions influencing land-use changes and their impacts on the supply of ecosystem services and human well-being. We utilise a transdisciplinary mixed-methods approach and the analytical lens of the social-ecological systems framework. Results reveal that the links between land-use changes, ecosystem services and human well-being are multifaceted; For example ecosystem services can decline, while human well-being increases. We explain this finding through three different pathways to impact (changes in the resource systems, the governance systems or the broader social, economic and political context). We conclude with implications of these results for future sustainable land governance.
Background: Long QT syndrome (LQTS) leads to arrhythmic events and increased risk for sudden cardiac death (SCD). Homozygous KCNH2 mutations underlying LQTS-2 have previously been termed "human HERG knockout" and typically express severe phenotypes. We studied genotype-phenotype correlations of an LQTS type 2 mutation identified in the homozygous index patient from a consanguineous Turkish family after his brother died suddenly during febrile illness.
Methods and Results: Clinical work-up, DNA sequencing, mutagenesis, cell culture, patch-clamp, in silico mathematical modelling, protein biochemistry, confocal microscopy were performed. Genetic analysis revealed a homozygous C-terminal KCNH2 mutation (p.R835Q) in the index patient (QTc ~506 ms with notched T waves). Parents were I° cousins – both heterozygous for the mutation and clinically unremarkable (QTc ~447 ms, father and ~396 ms, mother). Heterologous expression of KCNH2-R835Q showed mildly reduced current amplitudes. Biophysical properties of ionic currents were also only nominally changed with slight acceleration of deactivation and more negative V50 in R835Q-currents. Protein biochemistry and confocal microscopy revealed similar expression patterns and trafficking of WT and R835Q, even at elevated temperature. In silico analysis demonstrated mildly prolonged ventricular action potential duration (APD) compared to WT at a cycle length of 1000 ms. At a cycle length of 350 ms M-cell APD remained stable in WT, but displayed APD alternans in R835Q.
Conclusion: Kv11.1 channels affected by the C-terminal R835Q mutation display mildly modified biophysical properties, but leads to M-cell APD alternans with elevated heart rate and could precipitate SCD under specific clinical circumstances associated with high heart rates.
Next-generation sequencing (NGS) provides unrestricted access to the genome, but it produces ‘big data’ exceeding in amount and complexity the classical analytical approaches. We introduce a bioinformatics-based classifying biomarker that uses emergent properties in genetics to separate pain patients requiring extremely high opioid doses from controls. Following precisely calculated selection of the 34 most informative markers in the OPRM1, OPRK1, OPRD1 and SIGMAR1 genes, pattern of genotypes belonging to either patient group could be derived using a k-nearest neighbor (kNN) classifier that provided a diagnostic accuracy of 80.6±4%. This outperformed alternative classifiers such as reportedly functional opioid receptor gene variants or complex biomarkers obtained via multiple regression or decision tree analysis. The accumulation of several genetic variants with only minor functional influences may result in a qualitative consequence affecting complex phenotypes, pointing at emergent properties in genetics.
Background: In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they included mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent guidelines, mainly based on systolic blood pressure (SBP), cardiovascular disease (CVD) but not on frailty despite the high prevalence in oldest-old. This may lead to variation how General Practitioners (GPs) treat hypertension. Our aim was to investigate treatment variation of GPs in oldest-olds across countries and to identify the role of frailty in that decision.
Methods: Using a survey, we compared treatment decisions in cases of oldest-old varying in SBP, CVD, and frailty. GPs were asked if they would start antihypertensive treatment in each case. In 2016, we invited GPs in Europe, Brazil, Israel, and New Zealand. We compared the percentage of cases that would be treated per countries. A logistic mixed-effects model was used to derive odds ratio (OR) for frailty with 95% confidence intervals (CI), adjusted for SBP, CVD, and GP characteristics (sex, location and prevalence of oldest-old per GP office, and years of experience). The mixed-effects model was used to account for the multiple assessments per GP.
Results: The 29 countries yielded 2543 participating GPs: 52% were female, 51% located in a city, 71% reported a high prevalence of oldest-old in their offices, 38% and had >20 years of experience. Across countries, considerable variation was found in the decision to start antihypertensive treatment in the oldest-old ranging from 34 to 88%. In 24/29 (83%) countries, frailty was associated with GPs’ decision not to start treatment even after adjustment for SBP, CVD, and GP characteristics (OR 0.53, 95%CI 0.48–0.59; ORs per country 0.11–1.78).
Conclusions: Across countries, we found considerable variation in starting antihypertensive medication in oldest-old. The frail oldest-old had an odds ratio of 0.53 of receiving antihypertensive treatment. Future hypertension trials should also include frail patients to acquire evidence on the efficacy of antihypertensive treatment in oldest-old patients with frailty, with the aim to get evidence-based data for clinical decision-making.
CXCL12-CXCR4 signaling controls multiple physiological processes and its dysregulation is associated with cancers and inflammatory diseases. To discover as-yet-unknown endogenous ligands of CXCR4, we screened a blood-derived peptide library for inhibitors of CXCR4-tropic HIV-1 strains. This approach identified a 16 amino acid fragment of serum albumin as an effective and highly specific CXCR4 antagonist. The endogenous peptide, termed EPI-X4, is evolutionarily conserved and generated from the highly abundant albumin precursor by pH-regulated proteases. EPI-X4 forms an unusual lasso-like structure and antagonizes CXCL12-induced tumor cell migration, mobilizes stem cells, and suppresses inflammatory responses in mice. Furthermore, the peptide is abundant in the urine of patients with inflammatory kidney diseases and may serve as a biomarker. Our results identify EPI-X4 as a key regulator of CXCR4 signaling and introduce proteolysis of an abundant precursor protein as an alternative concept for chemokine receptor regulation.
The 23Al(p, γ)24Si stellar reaction rate has a significant impact on the light-curve emitted in X-ray bursts. Theoretical calculations show that the reaction rate is mainly determined by the properties of direct capture as well as low-lying 2+ states and a possible 4+ state in 24Si. Currently, there is little experimental information on the properties of these states.
In this proceeding we will present a new experimental study to investigate this reaction, using the surrogate reaction 23Al(d,n) at 47 AMeV at the National Superconducting Cyclotron Laboratory (NSCL). We will discuss our new experimental setup which allows us to use full kinematics employing the Gamma-Ray Energy Tracking In-beam Nuclear Array (GRETINA) to detect the γ-rays following the de-excitation of excited states of the reaction products and the Low Energy Neutron Detector Array (LENDA) to detect the recoiling neutrons. The S800 was used for identification of the 24Si recoils. As a proof of principle to show the feasibility of this concept the Q-value spectrum of 22Mg(d,n)23Al is reconstructed.
Darstellung und Eigenschaften des Coenzymanalogen Nicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid
(1970)
Kondensation des Quecksilbersalzes von 4-Methyl-5-acetyl-imidazol ** mit 1-Chlor-2.3.5-O-tribenzoyl-ribofuranose liefert das geschützte Ribosid 3. Zur Strukturaufklärung der Verbindung wurde 4-Methyl-5-acetyl-1-(β-D-0-2′.3′.5′-triacetyl-ribofuranosyl)-imidazol mit Methyljodid in das 3.4-Dimethyl-5-acetyl-1-(β-D-O-2′.3′.5′-triacetyl-ribofuranosyl)-imidazoliumjodid überführt und der Zuckerrest hydrolytisch gespalten. Das entstandene Imidazol-Derivat ist identisch mit 1.5-Dimethyl-4-acetyl-imidazol. 4-Methyl-5-acetyl-1- (β-D-ribofuranosyl) -imidazol wurde mit Aceton in das Isopropyliden-Derivat 4 überführt. Die Phosphorylierung zum Nucleosid-5′-phosphat (5) führten wir mit β-Cyanäthyl-phosphat durch. Durch Kondensation mit Nicotinamid-mononucleotid erhielten wir das Coenzymanaloge Nicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid (6). Die Verbindung liegt im oxydierten Zustand in gefaltener Form vor. Das Fluoreszenz-Anregungsspektrum der Dihydroverbindung zeigt keine Energieübertragung vom nichtfunktionellen 4-Methyl-5-acetyl-imidazol-Teil auf den Dihydronicotinamid-Ring. Das Coenzymanaloge weist eine größere Michaelis- Konstante im Test mit Lactat-Dehydrogenase aus Schweineherz *** auf als das natürliche Nicotinamid-adenindinucleotid ***. Die maximale Umsatzzahl ist trotz der schwächeren Bindung vergrößert. Das unterschiedliche Verhalten des Coenzymanalogen 6 gegenüber NAD läßt, neben der π-Bindung des nichtfunktionellen Teils, eine polare Gruppe im aktiven Zentrum des Enzyms vermuten, die die Ausrichtung des Coenzyms im Coenzym-Enzym-Komplex bewirkt.
Dihydronicotinamid-4-methyl-5-acetyl-imidazol-dinucleotid bildet einen fluoreszierenden Komplex mit der Lactat-Dehydrogenase, der dem des NADH-LDH-Komplexes sehr ähnlich ist.
Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
Background: The impact of MRI-lesion targeted (TB) and systematic biopsy (SB) Gleason score (GS) as a predictor for final pathological GS still remains unclear. Methods: All patients with TB + SB, and subsequent radical prostatectomy (RP) between 01/2014-12/2020 were analyzed. Rank correlation coefficient predicted concordance with pathological GS for patients’ TB and SB GS, as well as for the combined effect of SB + TB. Results: Of 159 eligible patients, 77% were biopsy naïve. For SB taken in addition to TB, a Spearman’s correlation of +0.33 was observed regarding final GS. Rates of concordance, upgrading, and downgrading were 37.1, 37.1 and 25.8%, respectively. For TB, a +0.52 correlation was computed regarding final GS. Rates of concordance, upgrading and downgrading for TB biopsy GS were 45.9, 33.3, and 20.8%, respectively. For the combination of SB + TB, a correlation of +0.59 was observed. Rates of concordance, upgrading and downgrading were 49.7, 15.1 and 35.2%, respectively. The combined effect of SB + TB resulted in a lower upgrading rate, relative to TB and SB (both p < 0.001), but a higher downgrading rate, relative to TB (p < 0.01). Conclusions: GS obtained from TB provided higher concordance and lower upgrading and downgrading rates, relative to SB GS with regard to final pathology. The combined effect of SB + TB led to the highest concordance rate and the lowest upgrading rate.
Members of the ATP‐binding cassette (ABC) transporter superfamily translocate a broad spectrum of chemically diverse substrates. While their eponymous ATP‐binding cassette in the nucleotide‐binding domains (NBDs) is highly conserved, their transmembrane domains (TMDs) forming the translocation pathway exhibit distinct folds and topologies, suggesting that during evolution the ancient motor domains were combined with different transmembrane mechanical systems to orchestrate a variety of cellular processes. In recent years, it has become increasingly evident that the distinct TMD folds are best suited to categorize the multitude of ABC transporters. We therefore propose a new ABC transporter classification that is based on structural homology in the TMDs:
Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
Methods: HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1–10.1), CD4 cell count 297 cells/mm3 (98–639), and HIV-RNA 5.2 log10copies/mL (4.7–5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5–10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4–23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2–54.8) versus 19.4 % (15.9–23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82–0.95; P < 0.001).
Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure.
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and a major cause of morbidity among children with pediatric rheumatic diseases. The management of JDM is very heterogeneous. The JDM working group of the Society for Pediatric Rheumatology (GKJR) aims to define consensus- and practice-based strategies in order to harmonize diagnosis, treatment and monitoring of JDM.
Methods: The JDM working group was established in 2015 consisting of 23 pediatric rheumatologists, pediatric neurologists and dermatologists with expertise in the management of JDM. Current practice patterns of management in JDM had previously been identified via an online survey among pediatric rheumatologists and neurologists. Using a consensus process consisting of online surveys and a face-to-face consensus conference statements were defined regarding the diagnosis, treatment and monitoring of JDM. During the conference consensus was achieved via nominal group technique. Voting took place using an electronic audience response system, and at least 80% consensus was required for individual statements.
Results: Overall 10 individual statements were developed, finally reaching a consensus of 92 to 100% regarding (1) establishing a diagnosis, (2) case definitions for the application of the strategies (moderate and severe JDM), (3) initial diagnostic testing, (4) monitoring and documentation, (5) treatment targets within the context of a treat-to-target strategy, (6) supportive therapies, (7) explicit definition of a treat-to-target strategy, (8) various glucocorticoid regimens, including intermittent intravenous methylprednisolone pulse and high-dose oral glucocorticoid therapies with tapering, (9) initial glucocorticoid-sparing therapy and (10) management of refractory disease.
Conclusion: Using a consensus process among JDM experts, statements regarding the management of JDM were defined. These statements and the strategies aid in the management of patients with moderate and severe JDM.
The single nucleotide polymorphism 118A>G of the human micro-opioid receptor gene OPRM1, which leads to an exchange of the amino acid asparagine (N) to aspartic acid (D) at position 40 of the extracellular receptor region, alters the in vivo effects of opioids to different degrees in pain-processing brain regions. The most pronounced N40D effects were found in brain regions involved in the sensory processing of pain intensity. Using the mu-opioid receptor-specific agonist DAMGO, we analyzed the micro-opioid receptor signaling, expression, and binding affinity in human brain tissue sampled postmortem from the secondary somatosensory area (SII) and from the ventral posterior part of the lateral thalamus, two regions involved in the sensory processing and transmission of nociceptive information. We show that the main effect of the N40D micro-opioid receptor variant is a reduction of the agonist-induced receptor signaling efficacy. In the SII region of homo- and heterozygous carriers of the variant 118G allele (n=18), DAMGO was only 62% as efficient (p=0.002) as in homozygous carriers of the wild-type 118A allele (n=15). In contrast, the number of [3H]DAMGO binding sites was unaffected. Hence, the micro-opioid receptor G-protein coupling efficacy in SII of carriers of the 118G variant was only 58% as efficient as in homozygous carriers of the 118A allele (p<0.001). The thalamus was unaffected by the OPRM1 118A>G SNP. In conclusion, we provide a molecular basis for the reduced clinical effects of opioid analgesics in carriers of mu-opioid receptor variant N40D.
The Coulomb Dissociation (CD) cross sections of the stable isotopes 92,94,100Mo and of the unstable isotope 93Mo were measured at the LAND/R3B setup at GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt, Germany. Experimental data on these isotopes may help to explain the problem of the underproduction of 92,94Mo and 96,98Ru in the models of p-process nucleosynthesis. The CD cross sections obtained for the stable Mo isotopes are in good agreement with experiments performed with real photons, thus validating the method of Coulomb Dissociation. The result for the reaction 93Mo(γ,n) is especially important since the corresponding cross section has not been measured before. A preliminary integral Coulomb Dissociation cross section of the 94Mo(γ,n) reaction is presented. Further analysis will complete the experimental database for the (γ,n) production chain of the p-isotopes of molybdenum.